Irene M Shui1,2, Chao-Jen Wong1, Shanshan Zhao3, Suzanne Kolb1, Ericka M Ebot2, Milan S Geybels1, Rohina Rubicz1, Jonathan L Wright1,4, Daniel W Lin1,4, Brandy Klotzle5, Marina Bibikova5, Jian-Bing Fan6, Elaine A Ostrander7, Ziding Feng8, Janet L Stanford1,9. 1. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. 2. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 3. Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina. 4. Department of Urology, University of Washington School of Medicine, Seattle, Washington. 5. Illumina, Inc, San Diego, California. 6. AnchorDx Corp, Guangzhou, Guangdong, China. 7. Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. 8. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 9. Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington.
Abstract
BACKGROUND: DNA methylation has been hypothesized as a mechanism for explaining the association between smoking and adverse prostate cancer (PCa) outcomes. This study was aimed at assessing whether smoking is associated with prostate tumor DNA methylation and whether these alterations may explain in part the association of smoking with PCa recurrence and mortality. METHODS: A total of 523 men had radical prostatectomy as their primary treatment, detailed smoking history data, long-term follow-up for PCa outcomes, and tumor tissue profiled for DNA methylation. Ninety percent of the men also had matched tumor gene expression data. A methylome-wide analysis was conducted to identify differentially methylated regions (DMRs) by smoking status. To select potential functionally relevant DMRs, their correlation with the messenger RNA (mRNA) expression of corresponding genes was evaluated. Finally, a smoking-related methylation score based on the top-ranked DMRs was created to assess its association with PCa outcomes. RESULTS: Forty DMRs were associated with smoking status, and 10 of these were strongly correlated with mRNA expression (aldehyde oxidase 1 [AOX1], claudin 5 [CLDN5], early B-cell factor 1 [EBF1], homeobox A7 [HOXA7], lectin galactoside-binding soluble 3 [LGALS3], microtubule-associated protein τ [MAPT], protocadherin γ A [PCDHGA]/protocadherin γ B [PCDHGB], paraoxonase 3 [PON3], synaptonemal complex protein 2 like [SYCP2L], and zinc finger and SCAN domain containing 12 [ZSCAN12]). Men who were in the highest tertile for the smoking-methylation score derived from these DMRs had a higher risk of recurrence (odds ratio [OR], 2.29; 95% confidence interval [CI], 1.42-3.72) and lethal disease (OR, 4.21; 95% CI, 1.65-11.78) in comparison with men in the lower 2 tertiles. CONCLUSIONS: This integrative molecular epidemiology study supports the hypothesis that smoking-associated tumor DNA methylation changes may explain at least part of the association between smoking and adverse PCa outcomes. Future studies are warranted to confirm these findings and understand the implications for improving patient outcomes. Cancer 2016;122:2168-77.
BACKGROUND: DNA methylation has been hypothesized as a mechanism for explaining the association between smoking and adverse prostate cancer (PCa) outcomes. This study was aimed at assessing whether smoking is associated with prostate tumor DNA methylation and whether these alterations may explain in part the association of smoking with PCa recurrence and mortality. METHODS: A total of 523 men had radical prostatectomy as their primary treatment, detailed smoking history data, long-term follow-up for PCa outcomes, and tumor tissue profiled for DNA methylation. Ninety percent of the men also had matched tumor gene expression data. A methylome-wide analysis was conducted to identify differentially methylated regions (DMRs) by smoking status. To select potential functionally relevant DMRs, their correlation with the messenger RNA (mRNA) expression of corresponding genes was evaluated. Finally, a smoking-related methylation score based on the top-ranked DMRs was created to assess its association with PCa outcomes. RESULTS: Forty DMRs were associated with smoking status, and 10 of these were strongly correlated with mRNA expression (aldehyde oxidase 1 [AOX1], claudin 5 [CLDN5], early B-cell factor 1 [EBF1], homeobox A7 [HOXA7], lectin galactoside-binding soluble 3 [LGALS3], microtubule-associated protein τ [MAPT], protocadherin γ A [PCDHGA]/protocadherin γ B [PCDHGB], paraoxonase 3 [PON3], synaptonemal complex protein 2 like [SYCP2L], and zinc finger and SCAN domain containing 12 [ZSCAN12]). Men who were in the highest tertile for the smoking-methylation score derived from these DMRs had a higher risk of recurrence (odds ratio [OR], 2.29; 95% confidence interval [CI], 1.42-3.72) and lethal disease (OR, 4.21; 95% CI, 1.65-11.78) in comparison with men in the lower 2 tertiles. CONCLUSIONS: This integrative molecular epidemiology study supports the hypothesis that smoking-associated tumor DNA methylation changes may explain at least part of the association between smoking and adverse PCa outcomes. Future studies are warranted to confirm these findings and understand the implications for improving patient outcomes. Cancer 2016;122:2168-77.
Authors: Corinne E Joshu; Alison M Mondul; Cari L Meinhold; Elizabeth B Humphreys; Misop Han; Patrick C Walsh; Elizabeth A Platz Journal: J Natl Cancer Inst Date: 2011-04-15 Impact factor: 13.506
Authors: Marina Bibikova; Bret Barnes; Chan Tsan; Vincent Ho; Brandy Klotzle; Jennie M Le; David Delano; Lu Zhang; Gary P Schroth; Kevin L Gunderson; Jian-Bing Fan; Richard Shen Journal: Genomics Date: 2011-08-02 Impact factor: 5.736
Authors: David Limsui; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Daniel J Weisenberger; Peter W Laird; Charles F Lynch; Kristin E Anderson; Amy J French; Robert W Haile; Lisa J Harnack; John D Potter; Susan L Slager; Thomas C Smyrk; Stephen N Thibodeau; James R Cerhan; Paul J Limburg Journal: J Natl Cancer Inst Date: 2010-06-29 Impact factor: 13.506
Authors: Judith S Knapp; Soum D Lokeshwar; Ulrich Vogel; Jörg Hennenlotter; Christian Schwentner; Mario W Kramer; Arnulf Stenzl; Axel S Merseburger Journal: World J Urol Date: 2012-08-15 Impact factor: 4.226
Authors: Styliani Mantziari; Pierre Allemann; Michael Winiker; Nicolas Demartines; Markus Schäfer Journal: World J Surg Date: 2018-07 Impact factor: 3.352
Authors: Paul Riviere; Abhishek Kumar; Elaine Luterstein; Lucas K Vitzthum; Vinit Nalawade; Reith R Sarkar; Alex K Bryant; John P Einck; Arno J Mundt; James D Murphy; Brent S Rose Journal: Prostate Cancer Prostatic Dis Date: 2019-10-17 Impact factor: 5.554
Authors: Catherine L Callahan; Matthew R Bonner; Jing Nie; Youjin Wang; Meng-Hua Tao; Peter G Shields; Catalin Marian; Kevin H Eng; Maurizio Trevisan; Jo L Freudenheim Journal: Cancer Causes Control Date: 2019-01-07 Impact factor: 2.532
Authors: Gregory Livshits; Ida Malkin; Maxim B Freidin; Yudong Xia; Fei Gao; Jun Wang; Timothy D Spector; Alex MacGregor; Jordana T Bell; Frances M K Williams Journal: Pain Date: 2017-06 Impact factor: 6.961
Authors: Jasper Wouters; Miguel Vizoso; Anna Martinez-Cardus; F Javier Carmona; Olivier Govaere; Teresa Laguna; Jesuchristopher Joseph; Peter Dynoodt; Claudia Aura; Mona Foth; Roy Cloots; Karin van den Hurk; Balazs Balint; Ian G Murphy; Enda W McDermott; Kieran Sheahan; Karin Jirström; Bjorn Nodin; Girish Mallya-Udupi; Joost J van den Oord; William M Gallagher; Manel Esteller Journal: BMC Med Date: 2017-06-05 Impact factor: 8.775